论文部分内容阅读
目的观察替吉奥胶囊单药在治疗大肠癌患者姑息手术后化疗的临床效果以及不良反应。方法将我院2014-06-2015-03接受大肠癌姑息手术后化疗的50例患者作为研究对象,将以上患者随机平均分为对照组和观察组,每组25例,其中对照组采用亚叶酸钙200mg/m2治疗,d1~d2,静脉输注,时间为2h,5-FU 500mg/m2,d1~d5,静脉输注,奥沙利铂静脉输注,85mg/m2,d1;观察组采用替吉奥(S-1)80mg/m2,药物使用方式为口服,2次/d早晚饭后服用,d1~d14,21d为一个治疗周期。结果观察组和治疗组的药物治疗有效率无明显差异,观察组腹泻发生率为12.0%,对照组腹泻发生率是48.0%;观察组出现1例口腔黏膜炎,发生率是4.0%,对照组出现11例口腔黏膜炎,发生率是44.0%。观察组不良反应率显著高于对照组,且P<0.05,差异有统计学意义。结论替吉奥(S-1)单药针对大肠癌患者股息手术后的治疗效果十分确切,且毒副作用比较少,胃肠不良反应比较轻,可以显著提升患者的生活质量,具有临床推广价值。
Objective To observe the clinical effect and side effects of TEGO capsules in the treatment of patients with colorectal cancer after palliative chemotherapy. Methods A total of 50 patients with colorectal cancer after palliative surgery received chemotherapy in our hospital from June 2014 to May 2015 were divided into control group and observation group randomly. The patients in each group were treated with leucovorin Calcium 200mg / m2 treatment, d1 ~ d2, intravenous infusion, time 2h, 5-FU 500mg / m2, d1 ~ d5, intravenous infusion of oxaliplatin intravenous infusion, 85mg / m2, d1; Tigio (S-1) 80mg / m2, the drug is used orally, 2 times / d and after taking meals, d1 ~ d14, 21d for a treatment cycle. Results There was no significant difference in the rate of drug treatment between observation group and treatment group. The incidence of diarrhea was 12.0% in observation group and 48.0% in control group. One case of oral mucositis was found in observation group, the incidence was 4.0% There were 11 cases of oral mucositis, the incidence was 44.0%. Adverse reaction rate in observation group was significantly higher than that in control group, and P <0.05, the difference was statistically significant. CONCLUSIONS: The single-agent treatment of S-1 for patients with colorectal cancer after the dividend operation is quite accurate and has few side effects and mild gastrointestinal adverse reactions. It can significantly improve the quality of life of patients and has clinical value of promotion.